Controlled Substances - As enacted, authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without the use of naloxone; adds that prescribing a buprenorphine product to nursing mother or prescribing an injectable mono product does not restrict certain healthcare providers from prescribing a buprenorphine product for the treatment of opioid use disorder without naloxone. - Amends TCA Title 53, Chapter 11.

HB 1984 expands access to buprenorphine treatment for opioid use disorder by allowing more healthcare providers to directly administer buprenorphine mono or buprenorphine without naloxone, as long as they act within their scope of practice. It specifically permits prescribing these medications to nursing mothers and patients with documented adverse reactions to naloxone, and clarifies that prescribing injectable forms doesn’t restrict providers from later prescribing non-naloxone buprenorphine. The bill amends Tennessee’s pharmacy law (TCA Title 53, Chapter 11) to remove barriers for these specific scenarios. This directly affects healthcare providers (like nurse practitioners or physician assistants) and patients seeking opioid treatment, particularly nursing mothers and those with allergies to naloxone.